Arbutus Biopharma ABUS
$4.02 −$0.05 (-1.23%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $3.98 -1.00%
Open$4.01
Prev close$4.07
Day range$3.97 – $4.09
Volume2.99M
Market cap$616.24M
P/E (TTM)3.6
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$299,000.00-43.5% YoY
Operating profit-$10.27M-23.9% YoY
Net profit$59.12M+863.6% YoY
Diluted EPS$0.30+850.0% YoY
Free cash flow$239.81M+4,222.6% YoY
Operating cash flow$239.81M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Operating margin80.1%
Net margin121.2%
Return on equity269.6%
Return on assets100.6%
Return on invested capital264.0%
Current ratio1.40
Liabilities / assets74.8%
Cash & investments$337.49M
Total debt$0.00
Net cash (debt)$337.49M
Free cash flow / sales121.8%
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $299,000.00 | $1.01M | $179.13M | $14.08M | $1.05M |
| Total Operating Revenue | $299,000.00 | $1.01M | $179.13M | $14.08M | $1.05M |
| Operating Expense | $10.57M | $6.77M | $10.01M | $41.13M | $8.70M |
| Selling and Admin Expenses | $7.96M | $3.87M | $5.89M | $15.89M | $3.69M |
| -General & Admin Expense | $7.96M | $3.87M | $5.89M | $15.89M | $3.69M |
| Research & Development | $2.62M | $2.90M | $4.12M | $25.24M | $5.01M |
| Operating Profit | -$10.27M | -$5.75M | $169.12M | -$27.05M | -$7.64M |
| Net Non-Operating Interest Income (Expense) | $2.36M | $824,000.00 | $798,000.00 | $3.97M | $859,000.00 |
| Non-Operating Interest Income | $2.37M | $842,000.00 | $815,000.00 | $4.07M | $877,000.00 |
| Non-Operating Interest Expense | $11,000.00 | $18,000.00 | $17,000.00 | $97,000.00 | $18,000.00 |
| Other Income (Expense) | $67.03M | -$216,000.00 | -$220,000.00 | -$10.42M | $3.03M |
| Gain on Sale of Security | $67.25M | -$3,000.00 | -$11,000.00 | $14,000.00 | $1,000.00 |
| Special Income (Charges) | -$221,000.00 | -$213,000.00 | -$209,000.00 | -$10.44M | $3.03M |
| -Less:Restructuring and Mergern & Acquisition | $221,000.00 | $213,000.00 | $209,000.00 | $11.11M | -$2.35M |
| Pretax Profit | $59.12M | -$5.14M | $169.70M | -$33.50M | -$3.76M |
| Net Profit | $59.12M | -$5.14M | $169.70M | -$33.50M | -$3.76M |
| Profit from Continuing Operations | $59.12M | -$5.14M | $169.70M | -$33.50M | -$3.76M |
| Net Income to Parent Company | $59.12M | -$5.14M | $169.70M | -$33.50M | -$3.76M |
| Net Income to Common Stockholders | $59.12M | -$5.14M | $169.70M | -$33.50M | -$3.76M |
| Basic EPS | $0.30 | -$0.03 | $0.88 | -$0.17 | -$0.01 |
| Diluted EPS | $0.30 | -$0.03 | $0.87 | -$0.17 | -$0.01 |
| -Gain on Sale of Property/Plant/Equipment | – | – | – | $674,000.00 | – |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $339.70M | $274.03M | $277.16M | $94.62M | $94.62M |
| Total Current Assets | $339.57M | $273.88M | $277.01M | $94.46M | $94.46M |
| Cash and Cash Equivalents & Short-Term Investments | $337.49M | $92.63M | $95.23M | $91.47M | $91.47M |
| -Cash and Cash Equivalents | $264.19M | $19.17M | $23.71M | $18.01M | $18.01M |
| -Short Term Investments | $73.30M | $73.45M | $71.52M | $73.46M | $73.46M |
| Receivables | $792,000.00 | $179.74M | $180.05M | $1.45M | $1.45M |
| -Accounts Receivable | $792,000.00 | $369,000.00 | $1.31M | $1.45M | $1.45M |
| Other Current Assets | $1.29M | $1.52M | $1.73M | $1.54M | $1.54M |
| Total Non-Current Assets | $131,000.00 | $142,000.00 | $153,000.00 | $162,000.00 | $162,000.00 |
| Net PPE | $0.00 | $10,000.00 | $22,000.00 | $32,000.00 | $32,000.00 |
| -Gross PPE | $245,000.00 | $245,000.00 | $246,000.00 | $245,000.00 | $245,000.00 |
| -Accumulated Depreciation | -$245,000.00 | -$235,000.00 | -$224,000.00 | -$213,000.00 | -$213,000.00 |
| Other Non-Current Assets | $131,000.00 | $132,000.00 | $131,000.00 | $130,000.00 | $130,000.00 |
| Total Liabilities | $253.95M | $15.29M | $16.99M | $18.04M | $18.04M |
| Total Current Liabilities | $241.93M | $3.36M | $5.11M | $6.01M | $6.01M |
| Payables | $320,000.00 | $373,000.00 | $1.46M | $1.17M | $1.17M |
| -Accounts Payable | $320,000.00 | $373,000.00 | $1.46M | $1.17M | $1.17M |
| Current Accrued Expenses | $11.19M | $2.32M | $2.77M | $3.65M | $3.65M |
| Short-Term Debt and Capital Lease Obligation | $328,000.00 | $514,000.00 | $631,000.00 | $547,000.00 | $547,000.00 |
| -Current Capital Lease Obligation | $328,000.00 | $514,000.00 | $631,000.00 | $547,000.00 | $547,000.00 |
| Other Current Liabilities | $230.10M | $160,000.00 | $245,000.00 | $640,000.00 | $640,000.00 |
| Total Non-Current Liabilities | $12.02M | $11.93M | $11.88M | $12.04M | $12.04M |
| Long Term Debt and Capital Lease Obligation | $0.00 | $0.00 | $0.00 | $199,000.00 | $199,000.00 |
| -Long Term Capital Lease Obligation | $0.00 | $0.00 | $0.00 | $199,000.00 | $199,000.00 |
| Other Non-Current Liabilities | $12.02M | $11.93M | $11.88M | $11.84M | $11.84M |
| Total Equity | $85.75M | $258.73M | $260.18M | $76.58M | $76.58M |
| Stockholders' Equity | $85.75M | $258.73M | $260.18M | $76.58M | $76.58M |
| Capital Stock | $1.46B | $1.45B | $1.44B | $1.42B | $1.42B |
| -Common Stock | $1.46B | $1.45B | $1.44B | $1.42B | $1.42B |
| Additional Paid-In Capital | -$167.33M | $74.32M | $74.26M | $83.32M | $83.32M |
| Retained Earnings | -$1.16B | -$1.22B | -$1.21B | -$1.38B | -$1.38B |
| Gains/Losses Not Affecting Retained Earnings | -$48.29M | -$48.24M | -$48.20M | -$48.10M | -$48.10M |
| -Other Receivables | – | $179.37M | $178.74M | – | – |
| Current Deferred Liabilities | – | – | – | $0.00 | $0.00 |
| Non-Current Deferred Liabilities | – | – | – | $0.00 | $0.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | $239.81M | -$6.02M | -$8.11M | -$39.64M | -$4.68M |
| Net cash flow from continuing operations | $239.81M | -$6.02M | -$8.11M | -$39.64M | -$4.68M |
| Net Income from Continuing Operations | $59.12M | -$5.14M | $169.70M | -$33.50M | -$3.76M |
| Depreciation & Depletion & Amortization | $10,000.00 | $11,000.00 | $11,000.00 | $363,000.00 | $11,000.00 |
| Other Non-Cash Items | $91,000.00 | $46,000.00 | $45,000.00 | -$3.22M | -$2.90M |
| Change in Working Capital | $179.80M | -$2.24M | -$178.87M | -$10.02M | $1.80M |
| -Change in Receivables | $178.95M | -$179.46M | $1.16M | $1.38M | -$129,000.00 |
| -Change in Prepaid Assets | $233,000.00 | $215,000.00 | -$195,000.00 | $1.70M | $1.30M |
| -Change in Payables and Accrued Expense | $806,000.00 | -$1.62M | -$985,000.00 | -$2.11M | $806,000.00 |
| -Change in Other Current Liabilities | -$185,000.00 | -$113,000.00 | -$105,000.00 | -$557,000.00 | -$177,000.00 |
| Net cash flow from investing | $504,000.00 | -$1.66M | $2.20M | $15.58M | -$1.36M |
| Net Cash Flow from Continuing Investing Activities | $504,000.00 | -$1.66M | $2.20M | $15.58M | -$1.36M |
| Net PPE Purchase and Sale | $0.00 | – | – | $364,000.00 | $355,000.00 |
| Net Investment Purchase and Sale | $504,000.00 | -$1.66M | $2.20M | $15.22M | -$1.72M |
| Financing Cash Flow | $4.71M | $3.15M | $11.62M | $5.72M | $1.64M |
| Net Cash Flow from Continuing Financing Activities | $4.71M | $3.15M | $11.62M | $5.72M | $1.64M |
| Proceeds from Stock Option Exercised | $4.71M | $3.15M | $11.62M | $5.72M | $1.64M |
| Ending Cash Balance | $264.19M | $19.17M | $23.71M | $18.01M | $18.01M |
| Net Change in Cash | $245.02M | -$4.53M | $5.71M | -$18.34M | -$4.40M |
| Beginning Cash Balance | $19.17M | $23.71M | $18.01M | $36.33M | $22.41M |
| Effect of Exchange Rate Changes | -$2,000.00 | -$4,000.00 | -$10,000.00 | $14,000.00 | $1,000.00 |
| Free Cash Flow | $239.81M | -$6.02M | -$8.11M | -$39.64M | -$4.68M |
| -Change In Other Working Capital | – | – | -$178.74M | -$10.43M | $0.00 |
| Net Other Investing Changes | – | – | -$1,000.00 | – | – |
| Gain/Loss from Continuing Operations | – | – | – | -$674,000.00 | – |
| Net Common Stock Issuance | – | – | – | $0.00 | $0.00 |
No comments yet — be the first to weigh in on ABUS.
Sign in to join the discussion.